IA
ARQT icon

IndexIQ Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

IndexIQ Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,598
Closed -$303K – 1323
2021
Q4 		$303K Sell
14,598
-943
-6% -$18.8K 0.01% 942
2021
Q3 		$371K Buy
15,541
+1,557
+11% +$35.5K 0.01% 881
2021
Q2 		$382K Sell
13,984
-926
-6% -$26.1K 0.01% 790
2021
Q1 		$431K Buy
+14,910
New +$466K 0.02% 420

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

IndexIQ Advisors's ARQT Position: Q1 2022 in Review

IndexIQ Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q1 2022, closing a stake of 14,598 shares — an estimated $303K sold.

IndexIQ Advisors first reported a position in ARQT in Q1 2021 and held it in 4 quarters. The position peaked at $431K in Q1 2021. 106 funds tracked by Wall St. Rank hold ARQT as of Q1 2022.

  • IndexIQ Advisors reported no remaining Arcutis Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 14,598 Arcutis Biotherapeutics shares in Q1 2022, an estimated $303K.
  • IndexIQ Advisors first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's Arcutis Biotherapeutics position peaked at $431K in Q1 2021.
  • 106 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.